For research use only. Not for therapeutic Use.
Valrocemide (TV1901) is a promising antiepileptic agent candidate that shows a broad spectrum of anticonvulsant activity.
In mice, valrocemide affords complete protection against maximal electroshock-, pentylenetetrazole-, picrotoxin-, and bicuculline-induced seizures and 6-Hz “psychomotor” seizures with median effective dose (ED50) values of 151, 132, 275, 248, and 237 mg/kg, respectively. Valrocemide is also effective in preventing sound-induced seizures in Frings audiogenic-seizure susceptible mice (ED50, 52 mg/kg). The median neurotoxic dose in mice is 332 mg/kg. After oral administration to rats, valrocemide is active in the MES test, with an ED50 of 73 mg/kg, and the median neurotoxic dose is 1,000 mg/kg. Intraperitoneal administration of 300 mg/kg of valrocemide to hippocampal kindled Sprague–Dawley rats block generalized seizures and shorten the afterdischarge duration significantly. Valrocemide also provides complete protection from focal seizures in the corneally kindled rats (ED50, 161 mg/kg)[1].
Catalog Number | I009993 |
CAS Number | 92262-58-3 |
Synonyms | N-(2-amino-2-oxoethyl)-2-propylpentanamide |
Molecular Formula | C10H20N2O2 |
Purity | ≥95% |
InChI | InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14) |
InChIKey | RALGCAOVRLYSMA-UHFFFAOYSA-N |
SMILES | CCCC(CCC)C(=O)NCC(=O)N |
Reference | [1]. Isoherranen N, et al. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001 Jul;42(7):831-6. |